Sage Therapeutics Announces Third Quarter 2016 Financial Results and Provides SRSE European Update

Go back to Sage Therapeutics Announces Third Quarter 2016 Financial Results and Provides SRSE European Update

SAGE Therapeutics (SAGE) Misses Q3 EPS by 5c

November 3, 2016 8:23 AM EDT

SAGE Therapeutics (NASDAQ: SAGE) reported Q3 EPS of ($1.15), $0.05 worse than the analyst estimate of ($1.10).

For earnings history and earnings-related data on SAGE Therapeutics (SAGE) click here.

... More